Navigation Links
Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Date:8/19/2007

Interim Phase 1 Data Confirms Safety and Tolerability

PLYMOUTH MEETING, Pa., Aug. 8 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced interim data from the first Phase 1 clinical study of trodusquemine (MSI-1436) for the treatment of obesity. Anthony DelConte, M.D., Vice President, Clinical Research and Development, presented "Trodusquemine: A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders," during the IBC 12th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics, August 6-8 in Boston.

The presentation summarized the clinical trial design of the single ascending dose Phase 1 study of MSI-1436 to evaluate safety and pharmacokinetics of the drug in healthy obese volunteers. Dr. DelConte provided interim data from the initial cohorts in the double-blind, randomized, placebo-controlled trial which included safety and pharmacokinetic (PK) data from 20 treated subjects and eight vehicle controls in four sequential dose groups. According to Dr. DelConte, PK profiles from the study thus far show a predictable pattern with minimal subject-to-subject variability and linearity across the range of doses studied. To date, no serious adverse events have been reported. It was emphasized that further study is needed to establish dose limiting toxicity and proof-of-concept in humans.

"These initial findings validate the preclinical safety and PK work done by Genaera scientists. We are encouraged by these findings and will continue to further characterize the safety profile and provide proof of concept for trodusquemine in obesity and type 2 diabetes management," commented Jack Armstrong, President and CEO. "We anticipate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Pharmion,Corporation (Nasdaq: PHRM ) and MethylGene ... and Drug Administration (FDA) has designated the,Companies, histone ... the treatment of acute myelogenous leukemia (AML) in ... product be intended for,treatment of a condition affecting ...
... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today ... 2 investigator-initiated trial of,PI-88 in combination with ... with prostate cancer. Dr. Gavin Marx,Royal North ... the,principal investigator conducting the trial, will present ...
Cached Medicine Technology:Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 2Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 3
(Date:7/31/2015)... ... , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest ... this new applicator in the United States as an upgrade to the CoolSmooth applicator ... original applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation ... Conference Center. The medical community, social workers, law enforcement, and government officials are ... in the effort to better understand and combat sex trafficking. Lead by sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that ... and VIPs at the 2015 Vans US Open of Surfing, July 25 through August ... claim “no added sugar” on the market, is a natural choice given the Open’s ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... looking to catch a new and refreshing show on Broadway, look no further than ... including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel Award, ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Should be considered along with LDL cholesterol ... 12 (HealthDay News) -- A new study showing ... of cardiac trouble strengthens the case for including ... , "Triglycerides traditionally have been viewed as second-class ...
... Global Trends, Progress and ... ANNAPOLIS, Md., Feb. 12 iJET Intelligent ... business resiliency services,today announced the publication of 2007 ... by iJET,s health intelligence team, the report,provides analysis ...
... CHICAGO (February 12, 2008) A new study published in ... of Surgeons shows that patients with a large support network ... prior to having a surgical procedure, which can have a ... findings suggest that it is important for clinicians to be ...
... of Frozen Desserts Nationwide Fuels ... Cefiore,s ... and one of the nation,s fastest-growing frozen yogurt,destinations, introduced today its ... 90% of U.S. households consuming frozen,desserts and many choosing frozen yogurt ...
... 12 Natural,Alternatives International, Inc. ("NAI") (Nasdaq: ... customized nutritional,supplements, today announced the appointment of Kenneth ... Mr. Wolf possesses over 20,years of manufacturing and ... as Chief Financial Officer with Phoenix Footwear Group, ...
... AKRON, Ohio, Feb. 12 Planning for the WKDD ... progressing effortlessly,when a company backed out at the last ... listening to the radio at just the right,moment., ... to WKDD, and [on-air personality] Matt Patrick was,discussing a ...
Cached Medicine News:Health News:Triglycerides Linked to Coronary Disease Risk 2Health News:Triglycerides Linked to Coronary Disease Risk 3Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 2Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 3Health News:Patients with larger social networks may fare better after an operation 2Health News:Latest Salvo Fired in Frozen Yogurt Wars as Southern California's Fastest-Growing Franchise - Cefiore - Launches New Chocolate Flavor 2Health News:Natural Alternatives International, Inc. Appoints New Chief Financial Officer 2Health News:Natural Alternatives International, Inc. Appoints New Chief Financial Officer 3Health News:Virtual Hold Technology Donates Toys, Helps Raise Money for WKDD's Annual Radiothon for Akron Children's Hospital 2
... invented the guidewire-mounted pressure sensor and ... Sensor is the only sensor on ... and flow. With significantly improved maneuverability ... your primary guidewire, as well as ...
... professional AED offeringthe G3 Pro. Our ... color display, provides manual override features, ... advanced technology available to provide healthcare ... emergency treatment of sudden cardiac arrest ...
... Electronic Stethoscope Model 4100WS features amplification and ... you to reduce ambient noise by an ... body sounds. Three frequency modes are available ... body sounds: Bell (20-200 Hz), Diaphragm (100-500 ...
... The iE33 is a 3D quantitative ... way echo exams are performed. Intelligent ... bring you revolutionary clinical performance and ... processes multiple data streams simultaneously and ...
Medicine Products: